The interaction of Thrombospondins with extracellular matrix proteins.
Tan, Kemin, and Jack Lawler. 2009. “The Interaction of Thrombospondins With Extracellular Matrix Proteins.”. Journal of Cell Communication and Signaling 3 (3-4): 177-87.
Search
Search results
203 results found
A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR.
Ren, Bin, Keli Song, Sareh Parangi, Taiguang Jin, Min Ye, Robin Humphreys, Mark Duquette, et al. 2009. “A Double Hit to Kill Tumor and Endothelial Cells by TRAIL and Antiangiogenic 3TSR.”. Cancer Research 69 (9): 3856-65.
The effect of thrombospondin-1 on breast cancer metastasis.
Yee, Karen O, Caitlin M Connolly, Mark Duquette, Shideh Kazerounian, Raymond Washington, and Jack Lawler. 2009. “The Effect of Thrombospondin-1 on Breast Cancer Metastasis.”. Breast Cancer Research and Treatment 114 (1): 85-96.
Latency associated peptide has in vitro and in vivo immune effects independent of TGF-beta1.
Ali, Naeem A, Alice A Gaughan, Charles G Orosz, Chris P Baran, Sara McMaken, Yijie Wang, Timothy D Eubank, et al. 2008. “Latency Associated Peptide Has in Vitro and in Vivo Immune Effects Independent of TGF-Beta1.”. PloS One 3 (4): e1914.
Heparin-induced cis- and trans-dimerization modes of the thrombospondin-1 N-terminal domain.
Tan, Kemin, Mark Duquette, Jin-huan Liu, Kumaran Shanmugasundaram, Andrzej Joachimiak, John T Gallagher, Alan C Rigby, Jia-huai Wang, and Jack Lawler. 2008. “Heparin-Induced Cis- and Trans-Dimerization Modes of the Thrombospondin-1 N-Terminal Domain.”. The Journal of Biological Chemistry 283 (7): 3932-41.
Thrombospondin-based antiangiogenic therapy.
Zhang, Xuefeng, and Jack Lawler. 2007. “Thrombospondin-Based Antiangiogenic Therapy.”. Microvascular Research 74 (2-3): 90-9.
The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size.
Zwicker, Jeffrey I, Flora Peyvandi, Roberta Palla, Rossana Lombardi, Maria Teresa Canciani, Andrea Cairo, Diego Ardissino, et al. 2006. “The Thrombospondin-1 N700S Polymorphism Is Associated With Early Myocardial Infarction Without Altering Von Willebrand Factor Multimer Size.”. Blood 108 (4): 1280-3.
Regulation of tumor angiogenesis by thrombospondin-1.
Ren, Bin, Karen O Yee, Jack Lawler, and Roya Khosravi-Far. 2006. “Regulation of Tumor Angiogenesis by Thrombospondin-1.”. Biochimica et Biophysica Acta 1765 (2): 178-88.
Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner.
Xie, Liang, Michael B Duncan, Jessica Pahler, Hikaru Sugimoto, Margot Martino, Julie Lively, Thomas Mundel, et al. 2011. “Counterbalancing Angiogenic Regulatory Factors Control the Rate of Cancer Progression and Survival in a Stage-Specific Manner.”. Proceedings of the National Academy of Sciences of the United States of America 108 (24): 9939-44.
Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1.
Niu, Qi, Carole Perruzzi, Daniel Voskas, Jack Lawler, Daniel J Dumont, and Laura E Benjamin. 2004. “Inhibition of Tie-2 Signaling Induces Endothelial Cell Apoptosis, Decreases Akt Signaling, and Induces Endothelial Cell Expression of the Endogenous Anti-Angiogenic Molecule, Thrombospondin-1.”. Cancer Biology & Therapy 3 (4): 402-5.